LEADER 04631nam 2200457 450 001 9910484717803321 005 20210311104540.0 010 $a3-030-56905-5 024 7 $a10.1007/978-3-030-56905-1 035 $a(CKB)4100000011631365 035 $a(DE-He213)978-3-030-56905-1 035 $a(MiAaPQ)EBC6420702 035 $a(PPN)252517466 035 $a(EXLCZ)994100000011631365 100 $a20210311d2021 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in host-directed therapies against tuberculosis /$fPetros C. Karakousis, Richard Hafner, Maria Laura Gennaro, editors 205 $a1st ed. 2021. 210 1$aCham, Switzerland :$cSpringer,$d[2021] 210 4$dİ2021 215 $a1 online resource (XIII, 332 p. 20 illus.) 311 $a3-030-56904-7 327 $aSection 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and V?9V?2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis. 330 $aThis book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective ? thus calling for pathway/factor enhancing drugs ? or maladaptive ? thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases. 606 $aImmunotherapy 615 0$aImmunotherapy. 676 $a616.079 702 $aHafner$b Richard 702 $aKarakousis$b Petros C. 702 $aGennaro$b Maria Laura 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910484717803321 996 $aAdvances in host-directed therapies against tuberculosis$92804770 997 $aUNINA